Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tirofiban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 20/20 | 0.98 |
| ▸ | ITGA2B known ✓ | P08514 | 20/20 | 0.98 |
| ▸ | ITGAV | P06756 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirofiban SCHEMBL155170 | 1.00 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL7388934 | 0.99 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41325 | 0.99 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL17721319 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL3685 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL618214 | 0.99 | ITGB3 (1.00) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL28858023 | 0.98 | ITGB3 (0.98) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL140366 | 0.97 | ITGB3 (0.96) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| Tirofiban SCHEMBL41326 | 0.96 | ITGB3 (0.95) | ITGB3ITGA2BITGAVCHRM2SLC6A4 | |
| SCHEMBL13873863 | 0.90 | ITGB3 (0.83) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2072 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250065012-A1 | DIRECTIONAL AND TEMPORAL RELEASE OF DRUGS FROM MEDICAL DEVICES | NANO THERAPEUTICS PRIVATE LIMITED (IN) | 2025-02-27 | — | — | US | claimed |
| CN-119438403-A | Detection method of 5-hydroxymethylfurfural in tirofiban hydrochloride injection compatibility test | 山东新时代药业有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119335093-A | Method for measuring sodium chloride content in tirofiban hydrochloride sodium chloride injection | 南京桦冠生物技术有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-118647417-A | Directional and time release of drugs from medical devices | 纳米疗法私人有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-115894306-B | Preparation method of N-N-butyl sulfonyl-L-tyrosine methyl ester | 武汉武药科技有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| CN-115181058-B | Composition and quality control method thereof | 武汉武药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | claimed |
| CN-117384084-A | Method for synthesizing tirofiban hydrochloride | 浙江浙邦制药有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-115448871-B | Preparation method of tirofiban hydrochloride | 中国药科大学 | 2023-07-11 | — | — | CN | claimed |
| US-6136804-A | ANTIISCHEMIC AGENTS, ANTITHROMBOTIC AGENTS, THROMBOTIC OCCLUSION AND ANTIPLATELET AGENT | MERCK & CO., INC. (US) | 2000-10-24 | — | — | US | claimed |
| US-6063584-A | Anticoagulant test | MERCK & CO., INC. (US) | 2000-05-16 | — | — | US | claimed |
| US-5978698-A | Angioplasty procedure using nonionic contrast media | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0946178-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| WO-1997035615-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |